Loading…
Repertoire Immune Medicines is developing programmable immune medicines by decoding the codes in the T cell repertoire to treat cancer and autoimmune diseases. Its DECODE platform maps the immune synapse to reveal actionable codes and enables the design of targeted immune therapies. The company pursues cancer and autoimmune disease programs, including collaborations such as a strategic partnership with Lilly to develop tolerizing therapies for autoimmune diseases.
AI named Repertoire in January 2026.